Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda names chief commerical officer

This article was originally published in Scrip

Executive Summary

Vanda Pharmaceuticals has named Tom Gibbs senior vice-president and chief commercial officer of the company.  Mr Gibbs has 20 years of experience in the pharmaceutical industry, including several senior-level leadership roles in global sales and marketing. Prior to joining Vanda he was vice-president of worldwide commercial operations at Bristol-Myers Squibb. Before joining Bristol-Myers Squibb, Mr Gibbs held the position of vice-president of US sales for Novartis Vaccines and Diagnostics.

You may also be interested in...



Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel